Titan Pharmaceuticals (TTNP)
(Delayed Data from NSDQ)
$5.50 USD
-0.11 (-1.95%)
Updated Aug 14, 2024 12:08 PM ET
After-Market: $5.32 -0.18 (-3.27%) 5:40 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Titan Pharmaceuticals, Inc. [TTNP]
Reports for Purchase
Showing records 81 - 100 ( 113 total )
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Research Coverage of TTNP Under Review
Provider: BRINSON PATRICK SECURITIES CORPORATION
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Moving to Market Outperform: Pathway to Approval Becoming Clearer.
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Despite Positive Panel Recommendation, FDA Issues Complete Response Letter
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Panel Recommends Approval of Probuphine
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Advisory Committee Releases Briefing Documents on Probuphine
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INITIATION: An Opioid Addiction Drug - Probuphine Implant, Poised for Approval
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Titan Pharmaceuticals under review due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.